ArticleInternational journal of cancer2025
Mammography screening reduced lifetime loss of employment duration and productivity for women with breast cancer: Real-world evidence of societal impacts.
Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mammography screening reduced lifetime loss of employment duration and productivity for women with breast cancer: Real-world evidence of societal impacts.International journal of cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The objective of this study is to evaluate the personal and societal impacts of mammography screening by estimating the life expectancy (LE), LE loss, lifetime employment duration (LED), LED loss, lifetime productivity (LP), and LP loss of women with breast cancer (BC). We recruited 113,169 women with BC diagnosis (2002-2017) from the Taiwan Cancer Registry, following survival until 2018. The monthly employment-population ratio (EMRATIO) and insured salary were abstracted from the National Health Insurance (NHI) until 2017. Lifetime survivals were extrapolated using relative survival with age-, sex-, and calendar-year-matched referents from vital statistics through a rolling-over algorithm, which were used in hazard models estimating LED and LP, with losses calculated by comparing the BC cohort to matched referents and relative loss percentages. We summarized the overall losses of LED and LP weighted by stage shifts between those who received screening versus those who did non-screening. We found no LED or LP losses for stages 0-I. LED losses for stages II-IV were 0.8, 2.3, and 5.1 years, respectively, with relative losses of LP being 9.4%, 30.2%, and 69.0%, respectively. Younger women faced more significant losses, with those aged 18-39 experiencing at least triple LED loss in stages III and IV compared to stage II. Mammography screening led to overall reductions of 2.9 years in LE, 0.6 years in LED, and 7.1% in LP, equivalent to a savings of US$ 7169. The mammography screening program in Taiwan improved the health and productivity of the population, especially among younger women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.